Pemphigus Foliaceus
Symptoms, Doctors, Treatments, Advances & More

Pemphigus Foliaceus Overview

Save information for later
Sign Up

Learn About Pemphigus Foliaceus

What is the definition of Pemphigus Foliaceus?
A rare superficial pemphigus disease characterized by multiple, pruritic, scaly, crusted cutaneous erosions, with flaky circumscribed patches, localized mostly on the face, scalp, trunk and extremities, often presenting an erythematous base. Mucosal involvement is rarely observed.
What are the alternative names for Pemphigus Foliaceus?
  • Pemphigus foliaceus
  • PF
Who are the top Pemphigus Foliaceus Local Doctors?
Elite in Pemphigus Foliaceus
Dr. Ron J. Feldman
Dermatology
Elite in Pemphigus Foliaceus
Dr. Ron J. Feldman
Dermatology
Referral required

Emory Clinic At 1525 Clifton Road

1525 Clifton Road Northeast, Fl3, 
Atlanta, GA 
404-778-3333
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ron Feldman is a Dermatologist practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 21 years. Dr. Feldman is rated as an Elite provider by MediFind in the treatment of Pemphigus Foliaceus. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Pemphigus Foliaceus, Pemphigus, Bullous Pemphigoid, and Pemphigus Vulgaris. Dr. Feldman is board certified in American Board Of Dermatology, 2010.

Elite in Pemphigus Foliaceus
Dr. Aimee Payne
Dermatology
Elite in Pemphigus Foliaceus
Dr. Aimee Payne
Dermatology
Referral may be required

CUIMC/Herbert Irving Pavilion

161 Fort Washington Ave, 
New York, NY 
914-768-8691
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aimee Payne is a Dermatologist practicing medicine in New York, New York. Dr. Payne is rated as an Elite provider by MediFind in the treatment of Pemphigus Foliaceus. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Pemphigus, Pemphigus Vulgaris, Pemphigus Foliaceus, and Bullous Pemphigoid.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Pemphigus Foliaceus
Dr. Sergei Grando
Dermatology
Elite in Pemphigus Foliaceus
Dr. Sergei Grando
Dermatology
Referral may be required

Office

850 Health Sciences Rd, 
Irvine, CA 
949-824-0606
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sergei Grando is a Dermatologist practicing medicine in Irvine, California. Dr. Grando is rated as an Elite provider by MediFind in the treatment of Pemphigus Foliaceus. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Pemphigus Vulgaris, Pemphigus, Pemphigus Foliaceus, and Bullous Pemphigoid.

View All Doctors
What are the latest Pemphigus Foliaceus Clinical Trials?
Evaluation of the Effectiveness of Clobetasol Propionate 0.05% and Photobiomodulation in the Management of Oral Lesions in Patients With Pemphigus Vulgaris. (Three-arm Randomized Controlled Clinical Study)
Evaluation of the Effectiveness of Clobetasol Propionate 0.05% and Photobiomodulation in the Management of Oral Lesions in Patients With Pemphigus Vulgaris. (Three-arm Randomized Controlled Clinical Study)
Enrollment Status: Recruiting
Publish Date: June 11, 2026
Intervention Type: Device, Drug
Study Phase: Not Applicable

Summary: Pemphigus vulgaris (PV) is a chronic, potentially life-threatening autoimmune mucocutaneous disorder that significantly impairs patients' quality of life. While systemic corticosteroids and immunosuppressants remain the standard of care, many patients suffer from persistent, painful oral lesions that exhibit delayed healing or poor response to conventional systemic protocols. This clinical trial i...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris
Who is this study for: Adult patients with Mucosal-Dominant Pemphigus Vulgaris
Enrollment Status: Recruiting
Publish Date: May 29, 2026
Intervention Type: Biological
Study Drug: Autologous Desmoglein 3 CAR-T Cells
Study Phase: Phase 1/Phase 2

Summary: A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center